TY - JOUR
T1 - Minimal Residual Disease Negativity Does Not Overcome Poor Prognosis in High-Risk Multiple Myeloma
T2 - A Single-Center Retrospective Study
AU - Kunacheewa, Chutima
AU - Lee, Hans C.
AU - Patel, Krina
AU - Thomas, Sheeba
AU - Amini, Behrang
AU - Srour, Samer
AU - Bashir, Qaiser
AU - Nieto, Yago
AU - Qazilbash, Muzzaffar H.
AU - Weber, Donna M.
AU - Feng, Lei
AU - Orlowski, Robert Z.
AU - Lin, Pei
AU - Manasanch, Elisabet E.
N1 - Publisher Copyright:
© 2020 Elsevier Inc.
PY - 2020/5
Y1 - 2020/5
N2 - Patients with multiple myeloma (MM) who experience deep remissions, including minimal residual disease (MRD) negativity, have better clinical outcomes compared to those do not. We aimed to describe the effect of testing for MRD negativity in a cohort of MM patients outside of a clinical trial. For most patients, MRD negativity supports improved clinical outcomes. However, in our cohort of patients with high-risk MM, MRD negativity does not seem to affect the overall poor prognosis.
AB - Patients with multiple myeloma (MM) who experience deep remissions, including minimal residual disease (MRD) negativity, have better clinical outcomes compared to those do not. We aimed to describe the effect of testing for MRD negativity in a cohort of MM patients outside of a clinical trial. For most patients, MRD negativity supports improved clinical outcomes. However, in our cohort of patients with high-risk MM, MRD negativity does not seem to affect the overall poor prognosis.
KW - Genetic risk
KW - High-risk myeloma
KW - Minimal residual disease
KW - Newly diagnosed myeloma
KW - Prognosis
UR - http://www.scopus.com/inward/record.url?scp=85078989364&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85078989364&partnerID=8YFLogxK
U2 - 10.1016/j.clml.2020.01.001
DO - 10.1016/j.clml.2020.01.001
M3 - Article
C2 - 32037287
AN - SCOPUS:85078989364
SN - 2152-2650
VL - 20
SP - e221-e238
JO - Clinical Lymphoma, Myeloma and Leukemia
JF - Clinical Lymphoma, Myeloma and Leukemia
IS - 5
ER -